Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.65 |
| ▸ | CTSS | P25774 | 1/20 | 0.65 |
| ▸ | CTSK | P43235 | 1/20 | 0.65 |
| ▸ | NMBR | P28336 | 7/20 | 0.61 |
| ▸ | TACR3 | P29371 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TACR1 | P25103 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CCKAR | P32238 | 1/20 | 0.55 |
| ▸ | CCKBR | P32239 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13649311 | 0.91 | CTSL (0.67) | CTSLCTSSCTSKNMBRMAPT | |
| SCHEMBL9833490 | 0.85 | CTSL (0.76) | CTSLCTSSCTSKNMBRTACR3 | |
| SCHEMBL15145404 | 0.84 | CTSL (0.77) | CTSLCTSSCTSKNMBRTACR3 | |
| SCHEMBL15145364 | 0.84 | CTSL (0.77) | CTSLCTSSCTSKNMBRTACR3 | |
| SCHEMBL17884340 | 0.82 | CTSL (0.74) | CTSLCTSSCTSKNMBRTACR3 | |
| SCHEMBL18879584 | 0.82 | CTSL (0.74) | CTSLCTSSCTSKNMBRTACR3 | |
| SCHEMBL17807348 | 0.82 | CTSL (0.80) | CTSLCTSSCTSKNMBRTACR3 | |
| SCHEMBL7521907 | 0.81 | CTSL (0.67) | CTSLCTSSCTSKNMBRTACR3 | |
| SCHEMBL7443477 | 0.81 | CTSL (0.72) | CTSLCTSSCTSKNMBRTACR3 | |
| SCHEMBL6021231 | 0.81 | CTSL (0.84) | CTSLCTSSCTSKNMBRTACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247472-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | FLUOFARMA (FR) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247472-A1 | TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS | CCNA1, MKI67, CCNT1 | CTSL 2778/4885CTSS 2707/4885CTSK 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.